Real‐world prevalence of <scp>PD</scp> ‐ <scp>L1</scp> positivity in early‐stage/metastatic triple‐negative breast cancer: primary results and pathology insights from the global retrospective observational <scp>VANESSA</scp> study
In this real-world study, PD-L1-positive prevalence was lower than in prospective trials assessing PD-L1 status centrally, lower in mTNBC than eTNBC, lower in smaller than larger tissue samples and lower by local than central assessment. These findings underline the importance of central PD-L1 testing on sufficiently large samples to ensure optimal selection for therapies targeting PD-(L)1 in mTNBC.
Authors
- Gyungyub Gong (ORCID: https://orcid.org/0000-0001-5743-0712)
- Alişan Zirtiloğlu (ORCID: https://orcid.org/0000-0002-3319-3983)
- Regula Deurloo
- Götz Hartleben
- Lazar Popović (ORCID: https://orcid.org/0000-0002-3278-6875)
- Tu Thai Anh
- Iman Estaytieh
- Sitki Tuzlali
- Enya Weber
- Paula Toro
- J. Mouta
- R. Dent
- Romualdo Barroso‐Sousa
- Nagi S El Saghir
- Nataša Medić‐Milijić
- Corrado D'Arrigo
Institutions
- Ulsan College (KR)
- Roche (Switzerland) (CH)
- University of Tuzla (BA)
- University of Novi Sad (RS)
- Kingston Maurward College (GB)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- American University of Beirut Medical Center (LB)
- Oncology Institute of Vojvodina (RS)
- Aga Khan University Nairobi (KE)
- HCMC Hospital of Dermato Venereology (VN)
- Hospital Universitário de Brasília (BR)
- National Cancer Centre Singapore (SG)
- Roche (Portugal) (PT)
- Roche (Lebanon) (LB)
- Roth and Rau (Germany) (DE)
Publication Details
- Journal
- Histopathology
- Published
- 2026-02-22
- DOI
- https://doi.org/10.1111/his.70091
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- F. Hoffmann-La Roche